Omya rebuilt and expanded its plant in Orgon, France, creating a substantially higher capacity for its functionalized calcium-carbonate product platform, a new packaging line, and an onsite warehouse.
Image courtesy of Omya
Omya (Oftringen, Switzerland) rebuilt and expanded its plant in Orgon, France, creating a substantially higher capacity for its functionalized calcium-carbonate product platform, a new packaging line, and an onsite warehouse. The facility produces mineral grades for food, pharmaceutical, nutraceutical, and cosmetic applications. Omya manufactures its products from natural limestone sourced in the surrounds of Orgon, with a very low environmental footprint.
“Omya has a strong commitment to responsible practices and stringent sustainability,” said Stefan Lander, vice president, consumer goods, group sales and marketing at Omya, in a press release. “Wherever we operate, we take into account the sensitivities of local communities and environments. Conserving biodiversity is always part of our decision-making process, and the cornerstone of land restoration and water management policy. Orgon is a perfect example of our long-standing principles, and we are pleased to have this modern facility in our corporate network. The Orgon plant expansion is a major step for us, providing our customers with natural and highly functional minerals while maintaining a focus on economic and ecological efficiency.”
To successfully operate the plant while preserving and protecting the delicate surroundings of the Alpilles natural park, Omya is considerate of the environment in all areas of its activity. With the help of local ecologists, the Orgon plant has initiated a re-cultivation plan to recreate areas where animals native to the area can thrive. In addition, the impact of quarry and plant activities on the wildlife are reduced to an absolute minimum and are closely monitored.
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.